Douglas D. Burkett
Keine laufenden Positionen mehr
Profil
Douglas D.
Burkett served as Chairman, President & Chief Executive Officer at Zila, Inc. from 2002 to 2007.
He also served as President & Chief Executive Officer at Champions Oncology, Inc. in 2009.
Burkett earned a doctorate degree from Arizona State University in 1994 and an undergraduate degree from Missouri Western State College in 1987.
Ehemalige bekannte Positionen von Douglas D. Burkett
| Unternehmen | Position | Ende |
|---|---|---|
| CHAMPIONS ONCOLOGY, INC. | Präsident | 31.12.2009 |
Zila, Inc.
 Zila, Inc. Medical SpecialtiesHealth Technology Zila, Inc., headquartered in Scottsdale, Arizona and founded in 1988, is a diagnostic company that offers prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite Plus with TBlue (“ViziLite Plus”), the company’s product for the detection of oral abnormalities that could lead to cancer. ViziLite Plus is a medical device for use in a popilation risking for oral cancer. Zila designs, manufactures and markets products sold directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler and oral pharmaceutical products for both in-office and home-care use | Vorstandsvorsitzender | 13.06.2007 |
Ausbildung von Douglas D. Burkett
| Missouri Western State College | Undergraduate Degree |
| Arizona State University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHAMPIONS ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Zila, Inc.
Zila, Inc. Medical SpecialtiesHealth Technology Zila, Inc., headquartered in Scottsdale, Arizona and founded in 1988, is a diagnostic company that offers prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite Plus with TBlue (“ViziLite Plus”), the company’s product for the detection of oral abnormalities that could lead to cancer. ViziLite Plus is a medical device for use in a popilation risking for oral cancer. Zila designs, manufactures and markets products sold directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler and oral pharmaceutical products for both in-office and home-care use | Health Technology |
